Navigation Links
HspE7 in Medical News

Nventa presents HspE7 data at international HPV conference

Preclinical Data Indicate New HspE7 Promotes More Potent Immune Responses SAN DIEGO, CA, Nov. 5 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today presented additional preclinical data on new HspE7 at the 24th International Papillomavirus conference, the largest annu...
HspE7 in Medical Technology

Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

All Patients in Cohort 3 Demonstrated Improvement in T-Cell Responses Further Supporting the Therapeutic Potential of HspE7 SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced positive immunological data from the third cohort of...

Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

- HspE7 Phase 2 Trial for Cervical Dysplasia to Begin Mid-2008 - SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of the fourth and final cohort of patients in its Phase 1...

Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

3 out of 4 Patients in Cohort 2 Demonstrate T-Cell Responses Indicating Potential HspE7 Therapeutic Benefit SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced interim immunological data from the first two cohorts of i...

Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the Company has completed enrollment and initiated dosing of the fourth and final cohort of patients in its Phase 1 dose escalation trial. This study examines the safety of its l...

Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial

- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly - SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of its third cohort of patients in a Phase 1 clinical trial o...

Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia

- 78 Percent of Patients Showed Complete Response or Reduction of Lesion Size by More than Fifty Percent - SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation today announced the presentation of positive results from a clinical trial examining the safety an...

Initiation of Coverage Informational Review Issued by Scimitar Equity Research

...tp://www.nventacorp.com . About HspE7, Nventa's Lead Product Candidate: hspe7 is a novel therapeutic vaccine candidate for the treatment of diseases caus...s (HPV), one of the most common sexually transmitted diseases in the world. hspe7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses ...
HspE7 in Biological Technology

Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial

SAN DIEGO, CA, Dec. 6 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the Company has completed enrollment and initiated dosing of the second cohort of patients in its Phase 1 dose escalation trial examining the safety of its lead candidate, HspE7...

Nventa announces publication of HspE7 data

- HspE7 Demonstrates Ability to Elicit Long-Lasting Tumor Protection In Vivo; Lead Candidate May Have Utility in HPV-infected Patients With Invasive Cancer and/or HIV - SAN DIEGO, CA, Sept. 24 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today ...

Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial

- Conference Call on September 13 to Discuss Phase 1 Trial and Other Major Milestones - SAN DIEGO, CA, Sept. 10 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced the initiation of its Phase 1 clinical trial to assess the safety...

Nventa updates progress of cervical dysplasia trial with new HspE7

-- Company Completes Enrollment in First Cohort -- SAN DIEGO, CA, Oct. 18 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced that the Company has completed enrollment of the first cohort in its Phase 1 clinical trial to assess the safety and tol...

Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights

...e fourth cohort were administered 500 mcg of hspe7 and 2,000 mcg of Poly-ICLC. These data support doses of 500 mcg of hspe7 and 1,000-2,000 mcg of Poly ICLC as appropri...nformation concerning: the immunologic activity of hspe7 in treating CIN; that we identified an optimal dos...

Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR

...nclude Phase 2 clinical studies that will evaluate hspe7 as a potential treatment for both low-grade cervic... do, that such studies will not support the use of hspe7 as a treatment for CIN 1 or CIN 2/3; that we will ...nned and that such studies will support the use of hspe7 as a treatment for CIN 1 and CIN 2/3; that we will...

Nventa Appoints Gordon H. Busenbark to Board of Directors

...at Burroughs Corporation. He received a bachelor of science degree in accounting and an MBA from the University of Utah in Salt Lake City. "Nventa's hspe7 therapeutic vaccine for the treatment of HPV-related diseases places the company at the center of a very exciting segment of the drug development indu...

Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results

... - Company Advancing Lead Candidate hspe7 into Phase 2 Clinical Trial in ...sia clinical trial examining the safety of new hspe7 leading to the recent completion of enrollment...conference demonstrating that co-administering hspe7 with certain adjuvants promotes more potent re...

Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results

...the first cohort of patients in the Company's hspe7 Phase 1 clinical trial in cervical intraepithelial...ce and Clinical Workshop that demonstrate that new hspe7 promotes more potent immune responses; - G...ccine Immunology demonstrating ability of new hspe7 to elicit long-lasting tumor protection in vivo, ...
Other Tags
(Date:8/29/2015)... AZ (PRWEB) , ... August 30, 2015 , ... On ... College (EMCC), one of the 10 regionally accredited Maricopa Community Colleges , ... to network with college students pursuing employment information and opportunities. , The Expo has ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... AB (PRWEB) , ... August 29, 2015 , ... ... heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at ... such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
(Date:8/28/2015)... ... , ... With the goal of furthering music education programs in schools, the ... County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best ... the underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... juillet 2015 La 10e Conférence internationale ... organisée par le BGI du 22 au 25 ... en Chine. La conférence célèbre son ... 2006, l,ICG est devenue l,une des réunions annuelles ... « omiques » et c,est aussi la plus dynamique, la ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
Other Contents